The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations

Sadeleştirilmiş öğe sayfası
dc.contributor.authorSoysal, Teoman
dc.contributor.authorEskazan, Ahmet Emre
dc.contributor.authorSerin, Istemi
dc.contributor.authorSadri, Sevil
dc.contributor.authorKeskin, Dilek
dc.contributor.authorYurttas, Nurgul Ozgur
dc.contributor.authorBerk, Selin
dc.contributor.authorOzunal, Isil Erdogan
dc.contributor.authorSalihoglu, Ayse
dc.contributor.authorAr, Muhlis Cem
dc.contributor.authorOngoren, Seniz
dc.contributor.authorBaslar, Zafer
dc.contributor.authorOzbek, Ugur
dc.contributor.authorAydin, Yildiz
dc.date.accessioned2025-10-16T15:23:25Z
dc.date.issued2019
dc.identifier.doi10.1016/j.clml.2019.03.028
dc.identifier.otherWOS:000477732800009
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/7984
dc.publisherCIG MEDIA GROUP, LP
dc.sourceCLINICAL LYMPHOMA MYELOMA \& LEUKEMIA
dc.subjectChronic myeloid leukemia
dc.subjectEuropean LeukemiaNet \\(ELN\\)
dc.subjectImatinib
dc.subjectTyrosine kinase inhibitor
dc.subjectWarning
dc.titleThe Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS